


Supplementary figure 1S



The median time to progression in HER2 positive trastuzumab treated breast cancer patients is significantly higher (10.2 months) than in metastatic breast cancer patients not submitted to trastuzumab based therapy (5.2 months). χ^2 test $p=0.04$.